Sustaining Innovation Analyst Day

IR thematic call on dupilumab

Sanofi and Regeneron hosted a conference call for the financial community focusing on investigational dupilumab following the late breaking data presentation from two trials evaluating dupilumab for inadequately controlled moderate-to-severe atopic dermatitis (SOLO 1 and SOLO 2) at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.

Related press releases

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies